The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

OncoGenex Pharmaceuticals Inc

Nasdaq: OGXI(*D)
Last

(U.S.) $0.50

Today's change+0.02 +3.95%
Updated March 24 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

OncoGenex Pharmaceuticals Inc

Nasdaq: OGXI(*D)
Last

(U.S.) $0.50

Today's change+0.02 +3.95%
Updated March 24 4:00 PM -4GMT. Delayed by at least 15 minutes.

OncoGenex Pharmaceuticals Inc up sharply

OncoGenex Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$0.02 or 3.95% to (U.S.)$0.50. Shares have lost 5.66% over the last five days, but are unchanged over the last year to date. This security has underperformed the S&P 500 by 53.40% during the last year.

Key company metrics

  • Open(U.S.) $0.48
  • Previous close(U.S.) $0.48
  • High(U.S.) $0.50
  • Low(U.S.) $0.48
  • Bid / Ask(U.S.) $0.34 / (U.S.) $0.58
  • YTD % change+0.020%
  • Volume54,949
  • Average volume (10-day)130,969
  • Average volume (1-month)197,682
  • Average volume (3-month)447,192
  • 52-week range(U.S.) $0.33 to (U.S.) $1.42
  • Beta1.77
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.67
Updated March 24 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.06%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue0023
Total other revenue--------
Total revenue0023
Gross profit--------
Total cost of revenue--------
Total operating expense6497
Selling / general / administrative2222
Research & development2455
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)2-110
Other operating expenses, total--------
Operating income-6-4-6-4
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-6-4-7-4
Income after tax-6-4-7-4
Income tax, total--------
Net income-6-4-7-4
Total adjustments to net income--------
Net income before extra. items-6-4-7-4
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-6-4-7-4
Inc. avail. to common incl. extra. items-6-4-7-4
Diluted net income-6-4-7-4
Dilution adjustment--------
Diluted weighted average shares30303030
Diluted EPS excluding extraordinary itemsvalue per share-0.19-0.12-0.23-0.12
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.13-0.17-0.18-0.11